Stifel lowered the firm’s price target on Definitive Healthcare (DH) to $5 from $6 and keeps a Buy rating on the shares. Q1 outperformed in terms of both revenue and EBITDA, but subscription revenue declined 5% quarter-over-quarter and 7% year-over-year, reflecting elevated customer churn, the analyst tells investors. Given Definitive’s costs are relatively fixed, the firm believes there will be pressure on both gross and EBITDA margins in 2025, but argues that management’s guidance of 480 basis points of EBITDA margin decline “seems reasonable and consistent with this dynamic.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH:
- Cautious Hold Rating for Definitive Healthcare Corp Amid Promising Developments and Retention Concerns
- Definitive Healthcare downgraded to Neutral from Buy at BTIG
- Definitive Healthcare Corp: Hold Rating Amid Positive Developments and Market Challenges
- Definitive Healthcare Reports Q1 2025 Financial Results
- Definitive Healthcare sees Q2 EPS 4c-5c, consensus 5c